These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 20029237

  • 1. GH therapy in Noonan syndrome: Review of final height data.
    Dahlgren J.
    Horm Res; 2009 Dec; 72 Suppl 2():46-8. PubMed ID: 20029237
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone therapy in Noonan syndrome: growth response and characteristics.
    Westphal O.
    Horm Res; 2009 Dec; 72 Suppl 2():41-5. PubMed ID: 20029236
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
    Binder G.
    Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
    [Abstract] [Full Text] [Related]

  • 5. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
    Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ.
    Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
    [Abstract] [Full Text] [Related]

  • 6. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
    Padidela R, Camacho-Hübner C, Attie KM, Savage MO.
    Horm Res; 2008 Sep; 70(3):129-36. PubMed ID: 18663312
    [Abstract] [Full Text] [Related]

  • 7. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
    Savage MO, Padidela R, Kirk JM, Malaquias AC, Jorge AA.
    Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
    [Abstract] [Full Text] [Related]

  • 8. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
    Blum WF, Cao D, Hesse V, Fricke-Otto S, Ross JL, Jones C, Quigley CA, Binder G.
    Horm Res; 2009 Jun; 71(3):167-72. PubMed ID: 19188742
    [Abstract] [Full Text] [Related]

  • 9. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.
    Romano AA, Dana K, Bakker B, Davis DA, Hunold JJ, Jacobs J, Lippe B.
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2338-44. PubMed ID: 19401366
    [Abstract] [Full Text] [Related]

  • 10. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D, Garel C, Limoni C, Czernichow P, Léger J.
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone treatment for short stature in children born small for gestational age.
    Jung H, Rosilio M, Blum WF, Drop SL.
    Adv Ther; 2008 Oct; 25(10):951-78. PubMed ID: 18836868
    [Abstract] [Full Text] [Related]

  • 12. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
    Binder G, Neuer K, Ranke MB, Wittekindt NE.
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5377-81. PubMed ID: 15985475
    [Abstract] [Full Text] [Related]

  • 13. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
    Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA.
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Growth in pre-pubertal children with myelomeningocele (MMC) on growth hormone (GH): the KIGS experience.
    Trollmann R, Bakker B, Lundberg M, Doerr HG.
    Pediatr Rehabil; 2006 Sep; 9(2):144-8. PubMed ID: 16449073
    [Abstract] [Full Text] [Related]

  • 16. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO, KIGS International Board.
    Horm Res; 2007 Sep; 68(2):53-62. PubMed ID: 17228181
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation of final height in patients with pituitary growth hormone deficiency who were treated with growth hormone replacement].
    Korpal-Szczyrska M, Dorant B, Kamińska H, Birkholz D, Niedźwiecki M.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Sep; 12(1):31-4. PubMed ID: 16704859
    [Abstract] [Full Text] [Related]

  • 18. Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency.
    Lagrou K, Xhrouet-Heinrichs D, Massa G, Vandeweghe M, Bourguignon JP, De Schepper J, de Zegher F, Ernould C, Heinrichs C, Malvaux P, Craen M.
    J Pediatr Endocrinol Metab; 2001 Sep; 14 Suppl 5():1249-60; discussion 1261-2. PubMed ID: 11964020
    [Abstract] [Full Text] [Related]

  • 19. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
    Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922
    [Abstract] [Full Text] [Related]

  • 20. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
    Choi JH, Lee BH, Jung CW, Kim YM, Jin HY, Kim JM, Kim GH, Hwang JS, Yang SW, Lee J, Yoo HW.
    Horm Res Paediatr; 2012 Dec; 77(6):388-93. PubMed ID: 22777296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.